Ying-Hao Shen

4PUBLICATIONS
8CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Infant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jun 02, 2025
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC.

Bu-Gang Liang, Yi-Min Zheng, Ming-Hao Xu

|May 13, 2024
CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils.

Pei Wang, Ming-Hao Xu, Wen-Xin Xu

|Feb 15, 2023
Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.

Ming-Hao Xu, Cheng Huang, Mei-Ling Li

|May 17, 2021
Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction.

Nan Xiao, Xiao-Long Li, Xiao-Dong Zhu

Pageof 1

Frequent Collaborators

2 joint publications

Hui-Chuan Sun

2 joint publications

Ming-Hao Xu

1 joint publications

Jian Zhou

1 joint publications

Jia Fan